NAMA Policy Statement: On the Issue of Raising a Patient’s Dose Without Their Consultation


Numerous studies have shown that dose is one of the most important aspects of methadone treatment and that patients who are given an adequate dose, know their dose and have some influence regarding their dose do better in treatment and remain in treatment (Ball and Ross, 1994; Caplehorn and Bell, 1991; Cooper, 1992; D’Annuno and Vaughn, 1992; GAO, 1990; Parrino, 1992; Zweben and Payte, 1990). Upon entering treatment the majority of addicts main concern is the methadone. This is what has attracted them to the program and can now be used therapeutically to build an alliance of trust between the patient and the program. As the patient experiences treatment and the “wise judgements” of the program staff, they begin to look to the program for support and help in stabilizing their lives.

Thus engaging the patient in the early phases of treatment makes rehabilitation all the easier for everyone: the patient and the counselor. Discussing simple concerns about the methadone brings the patient into the treatment process. When patients are involved in their treatment, and that includes dose, the outcome is for the better.

Before a patient’s dose can be changed it must be discussed with the patient, for how can a clinician know how to adjust the dose of a patient without first acquiring information that can only be obtained from the patient. Information about the “functionality” of the patient, how they feel and if the patient has produced urines positive for illicit drugs what is happening in their lives the cause this. Should a patient be experiencing a relapse then the wise clinician will find out the causes of it and then explain to the patient that perhaps a dose increase is necessary. The patient must understand why they may need an increase and how the increase will help them “function.” A short time spent with the patient will nurture a trusting relationship.

Certainly a dose should never be raised for only one positive urine and without the patient’s consent. Laboratories specializing in toxicology admit to approximately a 7% rate of false positives. The majority of clinics provide services to approximately 300 patients. Estimating from this then every month 21 patients are falsely accused of having positive urines. Considering this and the importance that patients place on dose it should never be changed for just one positive urine. Patients would be fearful of not being able to function because they are constantly being threatened with a dose increase which they have no control.

Adjusting a patient’s dose, either up or down without first discussing it with the patient is destructive to the therapeutic alliance. Such decisions foster the us/them siege mentality prevalent in many programs. The patient becomes angry towards the program and staff. They feel infantilized, objectified and left out of THEIR treatment. The human condition may tolerate such feelings of anger and powerlessness for a period of time but eventually for their own integrity the patient must rebel against the system. The Them!

It is interesting that in the early days of methadone treatment patients felt a pride and ownership towards their program. This was in spite of the many studies that patients were involved in. And perhaps that is the key — they felt as though they were ‘involved’ and an important part of making the program better. Their opinions were asked and considered. They had become engaged in the treatment process.

This past year I had the privilege to talk with Dr. Dole and the issue as to why treatment has degenerated to the point that it is no longer recognizable as the Dole-Nyswander program that was so successful. So I queried, “How did you know what to do and do it so well when you had never worked with addicts?” His remark was simple, “Well,” he said, “I had the best teacher Marie and she always taught me to first listen to the patient.”

For patients who are using other drugs a dose raise is probably in order. However, raising the dose without first discussing the reasons with the patient omits the most important aspect — the art of medicine. The patient’s concerns and even fears cannot be taken into account when their is no discussion about perhaps increasing the dose. Certainly, this is not quality methadone treatment.

References

Ball, J.C. and Ross, A. (1994). The Effectiveness of Methadone Maintenance Treatment. New York: Springer-Verlag.

Caplehorn, J.R.M. and Bell, J. (1991). Methadone dosage and retention of patients in maintenance treatment. Medical Journal of Australia (February 4) 154: 195-199.

Cooper, J.R. (1992). Ineffective use of psychoactive drugs: Methadone treatment is no exception. Journal of the American Medical Association 267(2): 281-282.

D’Aunno, T. and Vaughn, T.E. (1992). Variations in methadone treatment practices. Journal of the American Medical Association (January 8) 267(2): 253-258.

General Accounting Office (1990). Methadone Maintenance: Some Treatment Programs are Not Effective; Greater Federal Oversight Needed. GAO/HRD-90-104, 1990.

Parrino, M.W. (Chair & Editor) (1992). State Methadone Maintenance Treatment Guidelines Rockville, MD: U.S. Department of Health and Human Services, Center for Substance Abuse Treatment.

Zweben, J.E. and Payte, J.T. (1990). Methadone maintenance in the treatment of opioid dependence: A current perspective. Western Journal of Medicine 152(2): 588-599.


Similar Posts

  • NAMA Education Series

    Admin 12/01/2021

    Number 1 Methadone Maintenance and Patient Self AdvocacyBy Arlene Ford (March, 1991). Number 2 Drug Policy in the Age of AIDS – The Philosophy of Harm ReductionBy Rod Sorge (April, 1991). Number 3 Myths About Methadone By Emmett Velten (March, 1992). Number 4 Methadone, HIV Infection, and Immune FunctionBy Herman Joseph (August, 1994). Number 5…

  • Press Release – July 25, 1998

    Admin 07/21/2022

    National Alliance of Methadone Advocates Inc. FOR IMMEDIATE RELEASE    July 25, 1998 435 Second Avenue, New York, NY  10010 Contact: Joycelyn Woods              Policy Statement (212) 595-6262   Press Release     Mayor Guilianis Announcement About Plan to Close Methadone Programs in New York City Uses a Misunderstood Drug Treatment to Promote Celebrity at the…

  • CERTIFIED MEDICATION ASSISTED TREATMENT (MAT) ADVOCATE (CMA)

    Admin 09/12/2022

    Medication Assisted Treatment (MAT) Advocacy The National Alliance for Medication Assisted Recovery (NAMA-R) holds the view that every individual who believes in Medication Assisted Treatment (MAT) is at least a potential  Certified MAT Advocate (CMA). We encourage all supporters of MAT, patient and non-patient, to become Certified MAT Advocates so that all energies directed toward the advancement of…

  • |

    Risk Factors for HCV

    Admin 03/22/2023

    HCV Info Fact 24 August 2003 The risk factors for Hepatitis C Virus infection are: Intravenous drug use- Current or remote intravenous drug use accounts for 50% of new cases of HVC; 50% to 60% infected with HCV within 3 months of initiation of injection behavior Intranasal cocaine- Risk factor suggested by epidemiologic evidence Tattooing…

  • Publication Index

    Admin 02/09/2022

    Journal Articles Anderson, J. Methadone, history, pharmacology, outcomes, clinical issues and future trends. Advance 2002 April: 42-48. (PDF Format) Coates, E.A.; Brennan, D.; Logan, R.M.; Goss, A.N.; Scopacasa, B.; Spencer, A.J.; Gorkic, E. Hepatitis c and associated health problems. Australian Dental Journal 2000 45(2): 108-114. (PDF Format) D’Aunno, T.; Pollack, H.A. Changes in Methadone Treatment…

  • |

    national alliance for medication assisted recovery

    Admin 01/03/2023

    Dear Advocates: Since its beginning over 50 years ago methadone maintenance has been the most effective treatment for narcotic addiction. Evaluations worldwide over the past five decades have shown that methadone maintenance is the most successful treatment for opiate addiction, resulting in the termination both of opiate drug use and of criminal behavior.  In spite…